Heart 310 - Athena

(often associated with ATHENA trial contexts in heart disease research) is an experimental in vivo CRISPR gene-editing therapy designed to provide a one-time treatment for cardiovascular disease risk factors. It specifically targets the ANGPTL3 gene in the liver to permanently lower high levels of triglycerides (TG) and "bad" LDL cholesterol. 💡 Key Trial Results (Phase 1)

Average drops of ~55% at the highest dose, with some patients seeing up to 84% reduction .

Recent data from clinical studies, including updates as of late 2025, show significant efficacy in participants: ATHENA HEART 310

As of early 2026, the program is advancing toward to further evaluate long-term outcomes and safety in larger patient populations. This technology represents a potential shift from chronic disease management to a "one-and-done" therapeutic model for heart health.

The therapy is being tested for those with severe hypertriglyceridemia (sHTG), mixed dyslipidemia, and familial hypercholesterolemia (HoFH/HeFH). 🚀 Future Outlook (often associated with ATHENA trial contexts in heart

Targeted protein levels decreased by an average of 73%.

Mean reductions of ~49%, with peak effects reaching 87% . Recent data from clinical studies, including updates as

The treatment has been generally well-tolerated, with minor side effects like back pain or nausea reported during infusion. 🧬 Mechanism and Targets